fr   en
Edition n°143 - 16 December 2010

Browse by date
Or search by keyword

Slide down articles / Slide up articles

The stock market, fundraising and milestones
  • Kurma Biofund completes its first two investments
  • ThromboGenics raises EUR 56 m
  • EUR 15.5 m for SuppreMol
  • New investor for Covagen
  • First Ablynx molecule selected by Boehringer Ingelheim
  • Staggered payment for Symphogen under its agreement with Genentech
Clinical trials
  • Initial victory for Néovacs Kinoids
  • A conclusive phase III study for Amarin's Omega-3
  • End of the line for second Intercell vaccine